摘要
目的:二肽基肽酶-4(Dipeptidyl Peptidase-4,DPP-4)可以裂解包括胰高血糖素样肽-1(glucagonlike peptide 1,GLP-1)和抑胃肽(glucose-dependent insulinotropic polypeptide,GIP)在内的多种肽类激素,而前两者与2型糖尿病有着密切联系,是近年来2型糖尿病治疗领域研究的热点。本文就DDP-4抑制剂的作用特点、临床应用以及安全性和耐受性做一综述。方法:通过对国内外近期文献进行分析。结果与结论:DDP-4抑制剂不仅具有良好的降糖效果及保护β细胞功能,并且在糖尿病并发症进展中也起着一定的保护作用。
Objective: Dipeptidyl peptidase-4 (DDP-4) degrades several peptide hormones including glu- cagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). GLP-1 and GIP are closely related to type 2 diabetes. It is the hot area of the treatment of type 2 diabetes in recent years. In this article, we summarized the characteristics, clinical application, safety and tolerability of DDP-4 inhibitors. Methods: The medical literature in recent years at home and abroad was collected and analyzed. Results and Conclusion: DDP- 4 inhibitors have satisfactory hypoglycemic effects and protect β cells, and are beneficial for preventing diabetic complications as well.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2014年第23期2753-2757,共5页
Chinese Journal of New Drugs